Current analysis reveals insights on the treatment landscape and barriers to biomarker testing in metastatic cervical cancer patients.
Figure S3 shows respondents' likelihood of testing their patients for biomarkers in the future
No takes yet. Share an insight, caveat, or question.
Goh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: